Medication Attributable Adverse Events in Heart Failure Trials ScienceDirect Frontiers Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab From toxicity assessment to adaptive safety care: implementing comprehensive fast track safety evaluation for anticancer drug development ESMO Open Sermorelin: Benefits, FDA Status & Safety in 2025 Healthon Under reporting of harm in clinical trials The Lancet Oncology